VALENCIA, SPAIN--(Marketwired - Nov 17, 2016) - Zenosense, Inc. (OTCQB: ZENO) ("Zenosense", the "Company"), a healthcare technology company primarily focused on the development and commercialization of MIDS Cardiac™, a Point of Care ("POC") handheld device for the early detection of certain cardiac event biomarkers to significantly accelerate the triage, diagnosis, treatment and disposition of patients reporting chest pain and with suspected acute myocardial infarction (heart attack), is pleased to announce that it has received an independent Proof of Market report from MIDS Medical Limited ("MML"), our 40% owned joint venture based at Sci-Tech, Daresbury, UK.
The comprehensive report focuses on the commercial potential for MML's MIDS Cardiac development. MIDS Cardiac™ is intended to perform high sensitivity troponin assays at the POC, using a Magnetic Immunoassay Detection System ("MIDS technology"), an intellectual property utilized under license and being further developed by MML.
The report includes;
- Primary research consisting of in-depth expert interview and analysis conducted by various methods including online and postal questionnaires, telephone and face to face interviews.
- Secondary research consisting of desk based analysis of specialist publications, official statistics, government reports, industry publications, technical and scientific journals, patent databases and competitor websites.
- Business case development and market exploitation plans devised from an analysis of the secondary and primary research.
The report was originally paid for by Innovate UK, the UK Government innovation agency, by a grant made to the developer and owner of the MIDS technology in 2015, and updated in 2016 for MML by the author Inventya Ltd with input from MML. The full report is available on the following page at the Company's website - https://www.zenosense.com/proof-of-market
About Zenosense, Inc.
Zenosense Inc.'s primary focus, through our joint venture ownership in MIDS Medical Ltd., is the development of a cost-effective, hand-held Point of Care rapid cardiac diagnostic device, MIDS Cardiac™, and is also the holder of an exclusive global license agreement to develop and market effective medical devices for use in hospitals and primary healthcare settings targeting the early detection of both deadly bacteria and certain cancers in the exhaled breath of patients.
To find out more about Zenosense (OTCQB: ZENO), visit our website at www.zenosense.com.
Statements in this news release that are not statements of historical fact are forward-looking statements, which are subject to certain risks and uncertainties. Forward-looking statements can often be identified by words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes" and words of similar import. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Actual results may differ materially from those expressed or implied by forward-looking statements due to a variety of factors that may or may not be foreseeable or within the reasonable control of the Company. Readers are cautioned not to place undue reliance on such forward-looking statements. Additional information on risks and other factors that may affect the business and financial results of the Company can be found in filings of the Company with the U.S. Securities and Exchange Commission, including without limitation the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2015 filed on filed on May 23, 2016, and in Company reports filed subsequently thereto. Except as otherwise required by law, the Company disclaims any obligations or undertaking to publicly release any updates or revisions to any forward-looking statement contained in this news release to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. Respective statements concerning the development of both MIDS Cardiac™ and other devices under development have been made based on information obtained from MIDS Medical Ltd. and Zenon Biosystem, which the Company believes to be accurate, but have not been independently verified.